KRAS Exon 2 Mutations in Patients with Sporadic Colorectal Cancer: Prevalence Variations in Mexican and Latin American Populations.
José Luis Venegas-RodríguezJesús Arturo Hernández-SandovalMelva Gutiérrez-AnguloJosé Miguel Moreno-OrtizAnahí González-MercadoJorge Peregrina-SandovalHelen Haydee Fernanda Ramírez-PlascenciaBeatriz Armida Flores-LópezCarlos Rogelio Alvizo-RodríguezJesús Alonso Valenzuela-PérezSergio Cervantes-OrtizMaria de la Luz Ayala-MadrigalPublished in: Cancers (2024)
We searched for the prevalence of actionable somatic mutations in exon 2 of the KRAS gene in western Mexican patients with CRC. Tumor tissue DNA samples from 150 patients with sporadic CRC recruited at the Civil Hospital of Guadalajara were analyzed. Mutations in exon 2 of the KRAS gene were identified using Sanger sequencing, and the data were analyzed considering clinical-pathological characteristics. Variants in codon 12 (rs121913529 G>A, G>C, and G>T) and codon 13 (rs112445441 G>A) were detected in 26 patients (with a prevalence of 17%). No significant associations were found between these variants and clinical-pathological characteristics ( p > 0.05). Furthermore, a comprehensive search was carried out in PubMed/NCBI and Google for the prevalence of KRAS exon 2 mutations in Latin American populations. The 17 studies included 12,604 CRC patients, with an overall prevalence of 30% (95% CI = 0.26-0.35), although the prevalence ranged from 13 to 43% across the different data sources. Determining the variation and frequency of KRAS alleles in CRC patients will enhance their potential to receive targeted treatments and contribute to the understanding of the genomic profile of CRC.
Keyphrases
- risk factors
- copy number
- healthcare
- end stage renal disease
- chronic kidney disease
- wild type
- gene expression
- big data
- emergency department
- deep learning
- newly diagnosed
- south africa
- machine learning
- transcription factor
- risk assessment
- single cell
- drinking water
- artificial intelligence
- climate change
- peritoneal dialysis
- human health
- early onset
- circulating tumor
- drug induced